You are here

Michael Shelanski

Michael Shelanski
M.D., Ph.D.
Department Chairman
Pathology Delafield Professor of Pathology
Columbia University, College of Physicians and Surgeons

Professor Shelanski's laboratory is investigating the mechanism of memory disruption and synaptic dysfunction in Alzheimer's Disease. The lab uses a combination of cell culture and transgenic animal approaches in an attempt to understand why the over-expression of the amyloid precursor protein (APP) or direct application of its active peptide, A-beta, inhibits intracellular signaling in neuronal cells and leads to alterations of electrical activity, dendritic spine morphology and behavior. In the past two years, Shelanski's attention has been on the PKA-CREB signaling pathway and on the role of ubiquitin c-terminal hydrolase-L1 (Uch-L1) in regulating these events.

Select Publications: 

Lopez-Toledano MA, Shelanski ML. Increased neurogenesis in young transgenic mice overexpressing human APP(Sw, Ind).  J Alzheimers Dis. 2007 Nov;12(3):229-40.

Vitolo O, Gong B, Cao Z, Ishii H, Jaracz S, Nakanishi K, Arancio O, Dzyuba SV, Lefort R, Shelanski M. Protection against beta-amyloid induced abnormal synaptic function and cell death by Ginkgolide J.  Neurobiol Aging. 2007 Jul 17. [Epub ahead of print]

Padmanabhan J, Brown K, Shelanski ML. Cell cycle inhibition and retinoblastoma protein overexpression prevent Purkinje cell death in organotypic slice cultures.  Dev Neurobiol. 2007 May;67(6):818-26.